Study to Evaluate the Immune Response to Pneumococcal Vaccine in Alefacept-treated Adults With Chronic Plaque Psoriasis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

43 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-07-31

Study Completion Date

2008-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A vaccine causes the immune system to produce antibodies (immune response) to specific germs to protect the patient. This study evaluates the immune response to the pneumococcal vaccine in adults with Alefacept-treated chronic plaque psoriasis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Open-label Study to Evaluate Safety of Multiple Courses of IM Alefacept During Treatment of Chronic Plaque Psoriasis

NCT00692172

Psoriasis

COMPLETED PHASE3

Safety and Tolerability of Repeat Courses of IM Alefacept

NCT00233662

Chronic Plaque Psoriasis

COMPLETED PHASE3

A Phase 3 Study in Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Study Safety and Efficacy

NCT06643260

Plaque Psoriasis

NOT_YET_RECRUITING PHASE3

A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis

NCT01815424

Psoriasis

COMPLETED PHASE3

A Study to Assess the Efficacy and Safety of Alefacept in Psoriasis Patients for Whom Conventional Treatment is Ineffective or Inappropriate

NCT00673556

Chronic Plaque Psoriasis

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a 1 arm study designed to evaluate the immune response to pneumococcal vaccine in adults with Alefacept-treated chronic plaque psoriasis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Plaque Psoriasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Group Type EXPERIMENTAL

alefacept

Intervention Type DRUG

Intramuscular

polyvalent pneumococcal vaccine

Intervention Type DRUG

Injection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

alefacept

Intramuscular

Intervention Type DRUG

polyvalent pneumococcal vaccine

Injection

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Amevive® ASP0485 PNEUMOVAX® 23

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject has chronic plaque psoriasis
* Subject has at least 5% body surface area affected with psoriasis

Exclusion Criteria

* Skin disorder other than plaque psoriasis in affected area
* Previously immunized with any pneumococcal vaccine
* Subject has pustular or erythrodermic psoriasis
* Subject is immunocompromised
* Six or more herpes simplex virus outbreaks per year
* History or malignancy, chronic serious infection or hepatic disease

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No